{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:11:12Z","timestamp":1768583472447,"version":"3.49.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Vunakizumab, a novel IL-17A inhibitor, has demonstrated satisfactory efficacy and safety for the treatment of moderate-to-severe plaque psoriasis. This analysis aimed to assess the impact of treatment interruption on the efficacy and safety of vunakizumab in the treatment of this disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This\n                      <jats:italic>post-hoc<\/jats:italic>\n                      analysis used data from a phase 3 trial of vunakizumab (NCT04839016) that enrolled patients with moderate-to-severe plaque psoriasis. A total of 460 patients received vunakizumab treatment and were included in this analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over the 52-week treatment, 223 patients had one or more treatment interruption, and 237 patients had no treatment interruption. At week 52, patients with treatment interruption had lower achievement rates for Psoriasis Area and Severity Index (PASI) 75 (77.1% vs. 97.9%), PASI 90 (67.3% vs. 94.1%), PASI 100 (49.8% vs. 75.9%), and static Physician\u2019s Global Assessment of 0\/1 (62.8% vs. 93.7%) than those without interruption (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.001). Additionally, at week 52, patients with treatment interruption had lower improvements in patient-reported outcomes (PROs), including Dermatology Life Quality Index score, Itch Numerical Rating Scale score, EuroQol-5D and visual analogue scale score, and Short Form-36 Mental Component Score than those without interruption (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05). Further subgroup analysis indicated that the increased frequency of treatment interruption correlated with poorer PASI responses and PROs (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.05). The incidence of overall adverse events was similar between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Interrupted vunakizumab treatment reduced the clinical response and quality of life in patients with moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1639049","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:23:26Z","timestamp":1768541006000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase 3 trial"],"prefix":"10.3389","volume":"16","author":[{"given":"Qunyan","family":"Li","sequence":"first","affiliation":[{"name":"Graduate School, Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]},{"name":"Department of Dermatology, Tianjin lnstitute of lntegrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyun","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin lnstitute of lntegrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin lnstitute of lntegrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin lnstitute of lntegrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuotao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin lnstitute of lntegrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchen","family":"He","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin lnstitute of lntegrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2024.02.001","article-title":"Biologics for psoriasis","volume":"42","author":"Wride","year":"2024","journal-title":"Dermatol Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"adv00032","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and treatment: past, present and future aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.5716","article-title":"Biological therapy interruption and re-treatment in chronic plaque psoriasis","volume":"20","author":"Wang","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: A phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"16095","DOI":"10.3390\/ijms242216095","article-title":"Inflammation and psoriasis: A comprehensive review","volume":"24","author":"Man","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02110-8","article-title":"Vunakizumab: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.031","article-title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"92","author":"Yan","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17870","article-title":"Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation","volume":"36","author":"Stander","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.O.00030","article-title":"Scoring the SF-36 in orthopaedics: A brief guide","volume":"97","author":"Laucis","year":"2015","journal-title":"J Bone Joint Surg Am"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03030-5","article-title":"Efficacy and safety analysis in Chinese patients with moderate-to-severe psoriasis from a phase 3 trial: impact of treatment withdrawal and retreatment of ixekizumab","volume":"42","author":"Gao","year":"2025","journal-title":"Adv Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.5439","article-title":"Patient-reported outcome measures for health-related quality of life in patients with psoriasis: A systematic review","volume":"160","author":"Perez-Chada","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10469.x","article-title":"Patient-reported outcomes in psoriasis research and practice","volume":"165","author":"Otuki","year":"2011","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13691","article-title":"Patient-reported outcome measures in psoriasis: the good, the bad and the missing","volume":"172","author":"Kitchen","year":"2015","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13808","article-title":"Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Griffiths","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: A literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PTT.S328575","article-title":"Biologics in psoriasis: updated perspectives on long-term safety and risk management","volume":"12","author":"Al-Janabi","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis","volume":"45","author":"Kamata","year":"2018","journal-title":"J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S515389","article-title":"Impact of treatment interruption on the effectiveness of interleukin (IL)-17A inhibitors in plaque psoriasis: A retrospective analysis","volume":"18","author":"Jiang","year":"2025","journal-title":"Int J Gen Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:23:27Z","timestamp":1768541007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1639049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1639049"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1639049","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1639049"}}